SK Capital Partners Invests in Halo Pharmaceutical

January 7, 2015
Pharmaceutical Technology Editors

SK Capital Partners announced that it completed a strategic investment in Halo Pharmaceutical.

 

SK Capital Partners announced on Jan. 6, 2015 that it completed a controlling strategic growth investment in Halo Pharmaceutical. SK Capital Partners is a private investment firm with a focus on specialty materials, chemicals, and healthcare. Halo-a technology-focused contract development and manufacturing organization with a specialty in solid, semi-solid, and liquid dosage forms, especially controlled substances-is the sixth platform company for SK Capital Partners Fund III.

“As continuing owners of a significant share in the business, we are excited to partner with an industry-focused investor who can provide capital and resources to further improve our business and support our growth plans as we build our business … By having SK Capital as our partner, Halo will have the resources to acquire strategic assets that will increase our dosage forms offerings, formulation technologies, and enable superior customer service as a one-stop source for formulation development through commercialization,” said Mohd Asif, co-founder of Halo Pharmaceutical, in a press release.

Source: SK Capital Partners

Related Content:

PharmTech News | Supplier News